PIK3CA and breast cancer: In other recent studies performed on patients with stage II-III colorectal cancer [45] and early breast cancer [49] who received 5-fluorouracil-based and anthracycline-taxanes adjuvant chemotherapy respectively, concomitant presence of PIK3CA-TP53 mutations was a significantly poor predictive factor for OS [45] and DFS [49], also in adjusted analyses.